Persistent Asset Partners Ltd Makes New Investment in Repligen Corporation $RGEN

Persistent Asset Partners Ltd acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, HoldingsChannel.com reports. The fund acquired 3,902 shares of the biotechnology company’s stock, valued at approximately $532,000.

A number of other large investors have also made changes to their positions in RGEN. Global Retirement Partners LLC bought a new stake in shares of Repligen in the second quarter valued at about $655,000. GSA Capital Partners LLP acquired a new stake in Repligen during the second quarter worth about $336,000. Oppenheimer Asset Management Inc. bought a new position in Repligen during the second quarter valued at about $6,321,000. Wasatch Advisors LP increased its stake in Repligen by 27.9% during the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after acquiring an additional 346,720 shares during the period. Finally, Handelsbanken Fonder AB raised its holdings in Repligen by 11.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 22,070 shares of the biotechnology company’s stock valued at $3,011,000 after acquiring an additional 2,332 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

NASDAQ:RGEN opened at $166.83 on Monday. The firm has a market capitalization of $9.42 billion, a PE ratio of 228.53, a price-to-earnings-growth ratio of 3.04 and a beta of 1.03. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. Repligen Corporation has a 12-month low of $100.99 and a 12-month high of $175.77. The firm has a 50-day moving average price of $142.70 and a 200 day moving average price of $131.10.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The company had revenue of $204.13 million for the quarter, compared to the consensus estimate of $201.59 million. During the same period in the previous year, the business earned $0.26 earnings per share. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Research analysts anticipate that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Insider Activity at Repligen

In related news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RGEN. Wells Fargo & Company raised their price objective on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Evercore restated an “outperform” rating and set a $160.00 price objective on shares of Repligen in a research report on Monday, July 6th. Jefferies Financial Group restated a “hold” rating and issued a $142.00 target price on shares of Repligen in a research note on Tuesday, May 5th. Zacks Research raised Repligen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 30th. Finally, Citigroup upgraded shares of Repligen to a “buy” rating in a research note on Tuesday, July 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $166.43.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.